Ang Wei

Ang Wei

Auto-generated profile, based on publicly available information

Ang Wei

Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2022 in Blood
Verified
Journal Article
Closed access
PDF file
QZQing Zhang
Qing Zhang
YZYun-Ze Zhao
Yun-Ze Zhao
HMHong-Hao Ma
Hong-Hao Ma
DWDong Wang
Dong Wang
LCLei Cui
Lei Cui
RZRui Zhang
Rui Zhang
Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder characterized by hyperinflammation. Recently, ruxolitinib (RUX), targeting key cytokines in HLH, has shown promise for HLH treatment. However, there is a lack of robust clinical trials evaluating its efficacy, especially its utility as a frontline therapy. In this study (www.chictr.org.cn, ChiCTR2000031702), we designed ruxolitinib as a first-line agent for pediatric HLH and stratified the treatment based on its early response. Fifty-two newly diagnosed patients were enrolled. The overall response rate (ORR) of ruxolitinib monotherapy (day 28) was 69.2% (36/52), with 42.3% (22/52) achieving sustained complete remission (CR). All responders achieved their first response to ruxolitinib within 3 days. The response to ruxolitinib was significantly associated with the underlying etiology at enrollment (P = .009). Epstein-Barr virus (EBV)-HLH patients were most sensitive to ruxolitinib, with an ORR of 87.5% (58.3% in CR). After ruxolitinib therapy, 57.7% (30/52) of the patients entered intensive therapy with additional chemotherapy. Among them, 53.3% (16/30) patients achieved CR, and 46.7% (14/30) patients dominated by chronic active EBV infection-associated HLH (CAEBV-HLH) developed refractory HLH by week 8. The median interval to additional treatment since the first ruxolitinib administration was 6 days (range, 3-25 days). Altogether, 73.1% (38/52) of the enrolled patients achieved CR after treatment overall. The 12-month overall survival (OS) for all patients was 86.4% (95% confidence interval [CI], 77.1% to 95.7%). Ruxolitinib had low toxicity and was well tolerated compared with intensive chemotherapy. Our study provides clinical evidence for ruxolitinib as a frontline agent for pediatric HLH. The efficacy was particularly exemplified with stratified regimens based on the early differential response to ruxolitinib. This study was registered in the Chinese Clinical Trials Registry Platform (http://www.chictr.org.cn/) as ChiCTR2000031702.

13 February 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
TZTong Zou
Tong Zou
AWAng Wei
Ang Wei
HMHonghao Ma
Honghao Ma
HLHongyun Lian
Hongyun Lian
YLYali Liu
Yali Liu
TWTianyou Wang
Tianyou Wang

9 January 2023 in American Journal of Hematology
Verified
Journal Article
Closed access
LCLei Cui
Lei Cui
CWChan‐Juan Wang
Chan‐Juan Wang
HLHong‐Yun Lian
Hong‐Yun Lian
LZLi Zhang
Li Zhang
HMHong‐Hao Ma
Hong‐Hao Ma
RZRui Zhang
Rui Zhang

5 November 2021 in World Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
YLYan-Hui Luo
Yan-Hui Luo
JYJun Yang
Jun Yang
AWAng Wei
Ang Wei
GZGuang-Hua Zhu
Guang-Hua Zhu
BWBin Wang
Bin Wang
TWTianyou Wang
Tianyou Wang

15 November 2022 in Pediatric Investigation
Verified
Journal Article
Open access
YLYanhui Luo
Yanhui Luo
AWAng Wei
Ang Wei
BWBin Wang
Bin Wang
GZGuanghua Zhu
Guanghua Zhu
RZRui Zhang
Rui Zhang
TWTianyou Wang
Tianyou Wang
Importance: Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is considered the only effective treatment for chronic active Epstein–Barr virus infection (CAEBV). The clinical efficacy and safety of allo‐HSCT with different conditioning regimens in children with CAEBV remain unclear.Objective: To evaluate the effectiveness and safety of allo‐HSCT with the modified myeloablative conditioning (MAC) regimen for children with CAEBV and also the factors affecting the outcomes.Methods: We retrospectively analyzed children with CAEBV who underwent allo‐HSCT with the modified MAC regimen at Beijing Children's Hospital, Capital Medical University from October 2016 to June 2021. Data related to the clinical manifestations, engraftment, and outcome were extracted from the medical records.Results: The cohort comprised 41 patients (24 males, 17 females) with a median transplantation age of 92.6 (60.4, 120.7) months and a median follow‐up time of 28.2 (15.3, 40.2) months. Four patients (9.8%) died, among which three died from primary disease relapse, and one died from grade IV acute graft‐versus‐host diseases (aGVHD) after stopping treatment. The 3‐year overall survival (OS) and 3‐year event‐free survival (EFS) rates were 88.8% ± 5.4% and 85.0% ± 5.7%, respectively. The 3‐year OS and EFS did not significantly differ between the patients with hemophagocytic lymphohistiocytosis (HLH) and the patient without HLH (87.7% ± 6.8% vs. 91.7% ± 8.0%, P = 0.790; 85.0% ± 6.9% vs. 84.6% ± 10.0%, P = 0.921), or among the patients with complete remission, partial remission, and activity disease before HSCT (all P > 0.05). Multivariate analysis showed that grade III–IV aGVHD was a risk factor for mortality (Hazards ratio: 11.65, 95% confidence interval: 1.00, 136.06; P = 0.050).Interpretation: Allo‐HSCT with the modified MAC regimen is safe and effective for pediatric CAEBV. This treatment benefits patients with HLH or active disease. Patients with Grade III–IV aGVHD may be associated with worse outcomes.

20 April 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
WOWenxin Ou
Wenxin Ou
HMHonghao Ma
Honghao Ma
AWAng Wei
Ang Wei
YZYunze Zhao
Yunze Zhao
LZLiping Zhang
Liping Zhang
TWTianyou Wang
Tianyou Wang